Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer

Future Oncol. 2019 Mar;15(9):995-1006. doi: 10.2217/fon-2018-0818. Epub 2019 Jan 15.

Abstract

Aim: To dynamically investigate the prognostic value of albumin-to-alkaline phosphatase ratio (AAPR) in limited stage small-cell lung cancer.

Materials & methods: The AAPR within 1 week before and after chemoradiation therapy (pre- and post-AAPR) was collected and analyzed.

Results: Patients with low pre- or post-AAPR had shorter overall survival and progression-free survival than the high groups (p-values all <0.05). Post-AAPR was an independent prognostic factor for progression-free survival (p = 0.007) and overall survival (p = 0.003). The integration of pre- or post-AAPR improved the prognostic ability of Tumor, Node, Metastasis stage alone (0.55-0.64 and 0.68, respectively).

Conclusion: Post-AAPR is a reliable prognostic factor for limited stage small-cell lung cancer patients. The complementary value of AAPR to Tumor, Node, Metastasis stage is worth further validation in the future.

Keywords: albumin-to-alkaline phosphatase ratio; dynamically; limited stage small-cell lung cancer; prognostic; survival analysis.

MeSH terms

  • Alkaline Phosphatase / blood*
  • Biomarkers, Tumor / blood*
  • Chemoradiotherapy / methods
  • Female
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Predictive Value of Tests
  • Prognosis
  • Progression-Free Survival
  • Retrospective Studies
  • Serum Albumin, Human / analysis*
  • Small Cell Lung Carcinoma / blood
  • Small Cell Lung Carcinoma / mortality*
  • Small Cell Lung Carcinoma / pathology
  • Small Cell Lung Carcinoma / therapy
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • Alkaline Phosphatase
  • Serum Albumin, Human